TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04756037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Combination Therapy
Description: Participants will receive orally 1 fixed-dose combination tablet (relugolix 40 mg/E2 1 mg/NETA 0.5 mg) once daily.
Study: NCT06381713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensive combined phonetic-phonological intervention
Description: Children will receive phonetic articulation therapy supplemented by phonological principles. Consonants will be treated with emphasis on phonetic placement and shaping techniques. Phonetic articulation therapy includes five different steps:(1) identification of the target consonant using visual, tactile, and auditory feedback techniques,(2) discrimination between the used and targeted consonant, (3) variation and correction, (4) stabilize the target, and (5) maintenance of the target. A next level will be introduced when the child is able to correctly produce the sound in 80% of the time with minimal cues from the therapist. Multiple errors will be targeted simultaneously by focusing on a process. Child-friendly games will be played to illustrate the contrast between concepts, for example glottal 'throat' sounds and oral 'mouth' sounds. Exercises will be embedded in meaningful language contexts such as minimal pairs.~Therapy will be provided 2 times 30' per week for 20 weeks.
Study: NCT06016790

Intervention type: GENETIC
Intervention: cfDNA sequencing
Description: Multi-omics sequencing of cfDNA in peripheral venous blood.

Intervention type: GENETIC
Intervention: cfDNA sequencing
Description: Multi-omics sequencing of cfDNA in peripheral venous blood.
Study: NCT06412120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally (PO) daily as tablets at one of three possible dose levels, 100mg/day, 200mg/day or 300mg/day, based upon participant weight, platelet count, and certain drug combinations and conditions assessed at baseline.
Study: NCT05561517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 K running
Description: The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 K running
Description: The 5 K running competition will induce increased stress levels and thereby lead to increased levels of hyperglycemia.
Study: NCT04993365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The COVID-19 vaccine was manufactured by Sinovac Research \& Development Co., Ltd, and the EV71 vaccine was manufactured by Sinovac Biotech Co. The COVID-19 vaccine:600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection;The EV71 vaccine:Inactivated EV71 virus antigen no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Study: NCT05815108

Intervention type: OTHER
Intervention: NO INTERVENTION
Description: NO INTERVENTION
Study: NCT04687696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post Isometric Relaxation Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform an isometric contraction for 5 seconds in the horizontal abduction direction with 20% of the maximum muscle strength. After the relaxation, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between contractions.This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolytic Stretching Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier barrier. The participants will be asked to perform a contraction in the horizontal abduction direction with 20% of the maximum muscle strength. When the muscle contraction occurs, the arm will be moved quickly in 2-4 seconds towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretches. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group Group
Description: Athletes will be positioned in a modified cross-body position. They will be asked to actively bring their underlying arm in the direction of horizontal adduction up to the physiological barrier. Then, the arm will be moved towards horizontal adduction and 15 seconds active-assistive stretching will be applied. Participants will be given a 5-second rest period between stretching exercises. This stretching exercise will be applied in 5 repetitions in one session for 6 weeks 5 times a week.
Study: NCT05474300

Intervention type: OTHER
Intervention: mechanical ventilation
Description: Pressure controlled ventilation mode on mechanical ventilation
Study: NCT06345677

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ViXe Xombination
Description: Combination of Xeomin and the ultrasound based delivery system (Vibe) for intravesical administration of the drug in a minimally invasive procedure

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Sham
Description: Placebo identical in package and appearance to Xeomin together with all steps of Vibe device preparation and activation, but without the actual operation of the ultrasound energy
Study: NCT04583033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Treatment components include stimulus control, sleep restriction therapy, relaxation, and cognitive therapy. Each session will last approximately one hour and will be provided on line.
Study: NCT04243330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback
Description: The following components will be incorporated into the audit and feedback intervention: i) individualized facility performance data (site level), ii) frequent delivery intervals (monthly), iii) comparisons with other sites, iv) graphical and text form displays of information, v) constructive, non-punitive tone, vi) target performance or benchmark provided, and vii) specific actions or recommendations for meeting the target.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Facilitation
Description: Facilitation will be conducted by a team of facilitators who will employ the facilitation process to improve uptake of VA Risk ID. Trained external facilitators will flexibly deliver the facilitation process utilizing an integrated set of implementation strategies (e.g., stakeholder engagement, identification of barriers and facilitators, education, problem solving, the use of formative data, communication, and ongoing support).
Study: NCT05028400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging (LSCI)
Description: LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.
Study: NCT05102955

Intervention type: OTHER
Intervention: Observational questionnaires
Description: All one Group/ Visual Function Classification System(VFCS), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS), Communication Function Classification System(CFCS) Questionnaires will be assessed by the different raters (physiotherapists). But Visual Function Classification System(VFCS) will be assesed also by the parents.
Study: NCT04321759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy
Description: CET's group-based exercises are delivered for 1.5 hours each week in a group of 6-8 participants led by a clinician and an assistant, for one year. During each of three modules (basic concepts, social cognition, CET applications), the groups focus on acquisition of adult social milestones in perspective-taking, social context appraisal, and other aspects of social cognition, with psychoeducational lectures, homework assignments, and in-group exercises. Weekly supervision sessions for the clinician trainers will include review of how patients respond to the different demands of computer-based training and group-based exercises and guidance about improving engagement in both.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Skills Training
Description: The psychosocial component involves weekly skills training classes delivered over one year, with modules including Communicating Effectively, Making and Keeping Friends, Making the Most of Leisure Time, Healthy Living, Using Medications Effectively, and Making the Most of a Health Care Visit (Pratt et al., 2008). Participants attend two sessions each week (normally morning and afternoon of the same day): a 90-minute session focused on a specific skill and a 60-minute session in which the specific skill is used in role-play exercises.
Study: NCT06364085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation programming
Description: Participants will be brought in for their standard follow-up appointments at 4-weeks, 4-months, and 1-year post-surgery. In addition to the routine care, physiological data will be extracted from the implanted device and analyzed. The physiological data will be considered along with the standard epilepsy diary to assess epileptic burden and inform device programming.~Quality of life will be measured with a series of standard questionnaires pre-surgery and at the 1-year follow-up.
Study: NCT04517188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP
Description: Single topical administration
Study: NCT05726344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: 4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: 4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
Study: NCT05988671

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: Intraperitoneal route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intraperitoneal route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraperitoneal route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of dexamethasone + dexmedetomidine
Description: Intraperitoneal route
Study: NCT06195722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation
Description: parenteral drug simulation
Study: NCT06076915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame training
Description: During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame training
Description: During the exergame intervention period, the participants in the respective group will be asked to train at least two times per week for 10 minutes per session. The proposed 10 to 15 min-sessions can also be split up into multiple short training slots during the day, to thus reach the targeted 10 minutes. Moreover, the participants are allowed to train even more during their exergame-intervention period of six weeks. However, during the control period of six weeks, they are prohibited from training on the device.~The training program will start with four pre-defined programs of the Dividat Senso (Dividat AG, Schindellegi, Switzerland; CE certification) program. This training program will be adapted weekly by the investigator to generate new stimuli through varying games and thereby also further support the motivation.
Study: NCT05135650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and nasal swab sample collection
Study: NCT06029621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RATS for Thymectomy
Description: a minimally invasive surgical type for Thymoma: RATS

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS for Thymectomy
Description: a minimally invasive surgical type for Thymoma: VATS
Study: NCT04298983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG by mouth twice daily
Description: Abemaciclib will start with initiation of ADT, 3 months before RT, and pause 2 weeks prior to start of RT. Abemaciclib will resume with the first ADT administration post-radiation, which is about 1 month post radiation therapy. Abemaciclib will continue for a total of 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: ADT will be given every 3 months. ADT and Abemaciclib will pause 2 weeks prior to start of RT. ADT administration will resume with Abemaciclib post-radiation, which is about 1 month post radiation therapy. ADT will continue for a total of 24 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT will start 3 months after initiation of ADT and Abemaciclib. RT will be given as standard of care- 180 cGy x 28 fractions to the whole pelvis and the prostate will receive 250 cGy x 28 fractions. After RT is completed, both ADT and Abemaciclib will resume and continue for 24 months.
Study: NCT05966285

Intervention type: OTHER
Intervention: suture repair
Description: Suture repair was used to reinforce the abdominal wall, including Bassini, Ferguson, McVay, or Halsted technique.

Intervention type: OTHER
Intervention: mesh repair
Description: Mesh repair was conducted using a synthetic and biological mesh in the Lichtenstein or open preperitoneal techniques.
Study: NCT05121532

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-15 and Interleukin-22
Description: Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-15 and Interleukin-22
Description: Serum Interleukin-15 and Interleukin-22 in non segmental vitiligo
Study: NCT05385861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoliposomal irinotecan plus carboplatin
Description: Dose in phase 1 cohort:~Dose level 1= nanoliposomal irinotecan 100 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level 0= nanoliposomal irinotecan 80 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Dose level -1= nanoliposomal irinotecan 60 mg/m2 plus carboplatin AUC=4, intravenously both on day 1, q3wk~Carboplatin dose (mg) is calculated by the Calvert formula: AUC x (eGFR + 25). Cockcroft-Gault equation: eGFR (calculated Ccr)= \[(140-age) x weight x 0.85 (if female)\] / (72 x serum Cr). The maximum eGFR for dose calculation is 125 ml/min.~In Phase 2 Cohort Patients will be treated until disease progression, unacceptable toxicity or other condition meeting the treatment discontinuation criteria.
Study: NCT06582524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Description: SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are \< 24 months of age
Study: NCT04223310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virtual AAD TEST group
Description: 1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Preselect drug with optimal antiarrhythmic effects in the patient.~3. Take an AAD selected by virtual AAD simulation in patients who recur AF after catheter resection~4. Drug selection should be decided according to the guidelines.~5. A follow-up of rhythm follow-up has to be conducted according to the above study design.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empirical AAD group
Description: 1. Perform virtual AAD test using a voltage map acquired during de novo AF ablation procedure~2. Selection of AAD based on the experience of the attending physician, independent of the results of the virtual AAD test in patients who recur AF after catheter resection~3. Drug selection should be decided according to the guidelines.~4. A follow-up of rhythm follow-up has to be conducted according to the above study design.
Study: NCT06233071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone+ Ethinyl Estradiol Tablets-Test product
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: POND'S CHEMICAL THAILAND R.O.P

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone+ Ethinyl Estradiol Tablets-Reference product
Description: Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Manufactured by: Bayer Weimar GmbH und Co. KG, Germany
Study: NCT03804619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta-burst stimulation (aiTBS)
Description: aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
Study: NCT04700176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: During 28-day treatment cycles, patients will receive Dara 16 mg/kg intravenously (IV) at their current dose upon enrollment onto the study depending on their cycle. They will receive Dara depending on the cycle they are in. If they are on cycles 1-2 then they will receive Dara 16 mg/kg IV on days 1,8,15,22; if they are on cycles 3-6 they will receive Dara 16 mg/kg on days 1 and 15; and if they are on cycle 7 or beyond they will receive Dara 16 mg/kg on day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be administered at the patient's currently tolerated dose (4,3, or 2 mg po daily) on days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid
Description: ATRA will be administered in a divided dose of twice daily as an oral formulation at 45mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled Dara infusion. The last administration of ATRA will be given in the evening of the day that Dara was administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 40 mg once weekly on days 1,8,15 for patients 75 years old and younger and at 20 mg once weekly on days 1,8,15 for patients older than 75.
Study: NCT04793295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117